GSK announces that the European Commission has granted marketing authorization for Omjjara once-daily for the treatment of splenomegaly or related symptoms in adult patients with moderate to severe.
Martin Griesshammer, MD, PhD, Johannes Wesling University Clinic, discusses past and current efforts to improve treatment options for patients with polycythemia vera.
- Expanded Phase 2 data set continues to provide compelling rationale for move to registrational clinical program -
- Bomedemstat demonstrated durable clinical improvement in patients with ET who. | December 12, 2021